S&P 500   3,996.18 (-0.17%)
DOW   32,476.11 (-0.26%)
QQQ   311.68 (+0.43%)
AAPL   160.26 (+0.62%)
MSFT   277.81 (+1.47%)
META   203.92 (+0.87%)
GOOGL   105.72 (+0.76%)
AMZN   100.49 (-0.12%)
TSLA   197.24 (-0.17%)
NVDA   271.12 (+3.48%)
NIO   9.35 (+0.86%)
BABA   84.90 (+1.43%)
AMD   97.82 (+1.97%)
T   18.57 (+0.16%)
F   11.82 (+0.85%)
MU   58.73 (+0.17%)
CGC   1.96 (-0.40%)
GE   92.10 (-0.09%)
DIS   96.19 (-0.36%)
AMC   4.56 (+3.40%)
PFE   40.37 (-0.71%)
PYPL   75.71 (-1.32%)
NFLX   300.85 (-1.62%)
S&P 500   3,996.18 (-0.17%)
DOW   32,476.11 (-0.26%)
QQQ   311.68 (+0.43%)
AAPL   160.26 (+0.62%)
MSFT   277.81 (+1.47%)
META   203.92 (+0.87%)
GOOGL   105.72 (+0.76%)
AMZN   100.49 (-0.12%)
TSLA   197.24 (-0.17%)
NVDA   271.12 (+3.48%)
NIO   9.35 (+0.86%)
BABA   84.90 (+1.43%)
AMD   97.82 (+1.97%)
T   18.57 (+0.16%)
F   11.82 (+0.85%)
MU   58.73 (+0.17%)
CGC   1.96 (-0.40%)
GE   92.10 (-0.09%)
DIS   96.19 (-0.36%)
AMC   4.56 (+3.40%)
PFE   40.37 (-0.71%)
PYPL   75.71 (-1.32%)
NFLX   300.85 (-1.62%)
S&P 500   3,996.18 (-0.17%)
DOW   32,476.11 (-0.26%)
QQQ   311.68 (+0.43%)
AAPL   160.26 (+0.62%)
MSFT   277.81 (+1.47%)
META   203.92 (+0.87%)
GOOGL   105.72 (+0.76%)
AMZN   100.49 (-0.12%)
TSLA   197.24 (-0.17%)
NVDA   271.12 (+3.48%)
NIO   9.35 (+0.86%)
BABA   84.90 (+1.43%)
AMD   97.82 (+1.97%)
T   18.57 (+0.16%)
F   11.82 (+0.85%)
MU   58.73 (+0.17%)
CGC   1.96 (-0.40%)
GE   92.10 (-0.09%)
DIS   96.19 (-0.36%)
AMC   4.56 (+3.40%)
PFE   40.37 (-0.71%)
PYPL   75.71 (-1.32%)
NFLX   300.85 (-1.62%)
S&P 500   3,996.18 (-0.17%)
DOW   32,476.11 (-0.26%)
QQQ   311.68 (+0.43%)
AAPL   160.26 (+0.62%)
MSFT   277.81 (+1.47%)
META   203.92 (+0.87%)
GOOGL   105.72 (+0.76%)
AMZN   100.49 (-0.12%)
TSLA   197.24 (-0.17%)
NVDA   271.12 (+3.48%)
NIO   9.35 (+0.86%)
BABA   84.90 (+1.43%)
AMD   97.82 (+1.97%)
T   18.57 (+0.16%)
F   11.82 (+0.85%)
MU   58.73 (+0.17%)
CGC   1.96 (-0.40%)
GE   92.10 (-0.09%)
DIS   96.19 (-0.36%)
AMC   4.56 (+3.40%)
PFE   40.37 (-0.71%)
PYPL   75.71 (-1.32%)
NFLX   300.85 (-1.62%)
NASDAQ:CPRX

Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

$16.43
-0.10 (-0.60%)
(As of 03/22/2023 11:59 AM ET)
Add
Compare
Today's Range
$16.40
$16.74
50-Day Range
$14.34
$21.05
52-Week Range
$6.15
$22.11
Volume
305,050 shs
Average Volume
2.39 million shs
Market Capitalization
$1.74 billion
P/E Ratio
22.20
Dividend Yield
N/A
Price Target
$21.50

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
29.9% Upside
$21.50 Price Target
Short Interest
Bearish
10.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.50mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
27.12%
From $1.18 to $1.50 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

110th out of 983 stocks

Pharmaceutical Preparations Industry

36th out of 478 stocks


CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

This Trade Strategy Outpaces Almost Anything
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Check Out What Whales Are Doing With CPRX
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Up 5.7%
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Why Catalyst Pharmaceuticals Shares Are Moving
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
11/09/2021
Today
3/22/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$21.50
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.50
Forecasted Upside/Downside
+30.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$83.08 million
Pretax Margin
48.89%

Debt

Sales & Book Value

Annual Sales
$214.20 million
Cash Flow
$0.84 per share
Book Value
$2.89 per share

Miscellaneous

Free Float
90,757,000
Market Cap
$1.75 billion
Optionable
Optionable
Beta
1.16

Social Links


Key Executives

  • Patrick J. McEnanyPatrick J. McEnany
    Chairman, President & Chief Executive Officer
  • Steven R. MillerSteven R. Miller
    Chief Operating & Scientific Officer
  • Alicia GrandeAlicia Grande
    CFO, Treasurer, Principal Accounting Officer & VP
  • Gary IngenitoGary Ingenito
    Chief Medical & Regulatory Officer
  • Stanley Iyadurai
    Vice President-Clinical Development













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 1 year price targets for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $25.00. On average, they expect the company's share price to reach $21.50 in the next year. This suggests a possible upside of 30.1% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 11.1% and is now trading at $16.53.
View the best growth stocks for 2023 here
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 10,370,000 shares, an increase of 6.5% from the February 13th total of 9,740,000 shares. Based on an average daily volume of 2,360,000 shares, the short-interest ratio is currently 4.4 days. Approximately 10.6% of the company's stock are short sold.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, hitting the consensus estimate of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analyst estimates of $34.47 million. Catalyst Pharmaceuticals had a net margin of 38.78% and a trailing twelve-month return on equity of 32.21%. During the same quarter in the previous year, the business posted $0.11 EPS.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals issued an update on its fourth quarter 2022 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $61.00 million-$61.00 million, compared to the consensus revenue estimate of $56.84 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.22%), Dimensional Fund Advisors LP (2.22%), Two Sigma Investments LP (1.85%), Two Sigma Advisers LP (1.74%), Geode Capital Management LLC (1.69%) and Morgan Stanley (1.67%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $16.53.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.75 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $0.74 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 3/22/2023 by MarketBeat.com Staff